131 related articles for article (PubMed ID: 1670617)
1. Carbamazepine maintenance treatment in outpatient schizophrenics.
Carpenter WT; Kurz R; Kirkpatrick B; Hanlon TE; Summerfelt AT; Buchanan RW; Waltrip RW; Breier A
Arch Gen Psychiatry; 1991 Jan; 48(1):69-72. PubMed ID: 1670617
[TBL] [Abstract][Full Text] [Related]
2. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.
Okuma T; Yamashita I; Takahashi R; Itoh H; Otsuki S; Watanabe S; Sarai K; Hazama H; Inanaga K
Acta Psychiatr Scand; 1989 Sep; 80(3):250-9. PubMed ID: 2573234
[TBL] [Abstract][Full Text] [Related]
3. A double-blind trial of carbamazepine in negative symptom schizophrenia.
Nachshoni T; Levin Y; Levy A; Kritz A; Neumann M
Biol Psychiatry; 1994 Jan; 35(1):22-6. PubMed ID: 7909450
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.
Ruskin PE; Nyman G
J Nerv Ment Dis; 1991 Apr; 179(4):212-4. PubMed ID: 1672547
[TBL] [Abstract][Full Text] [Related]
5. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
6. Brief intermittent neuroleptic prophylaxis for selected schizophrenic out-patients.
McClelland HA; Harrison G; Soni SD
Br J Psychiatry; 1989 Nov; 155():702-6. PubMed ID: 2575424
[No Abstract] [Full Text] [Related]
7. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
Spina E; De Domenico P; Ruello C; Longobardo N; Gitto C; Ancione M; Di Rosa AE; Caputi AP
Int Clin Psychopharmacol; 1994; 9(4):281-5. PubMed ID: 7868850
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
9. Intermittent vs maintenance medication in schizophrenia. Two-year results.
Herz MI; Glazer WM; Mostert MA; Sheard MA; Szymanski HV; Hafez H; Mirza M; Vana J
Arch Gen Psychiatry; 1991 Apr; 48(4):333-9. PubMed ID: 1672588
[TBL] [Abstract][Full Text] [Related]
10. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study.
Klein E; Bental E; Lerer B; Belmaker RH
Arch Gen Psychiatry; 1984 Feb; 41(2):165-70. PubMed ID: 6365015
[TBL] [Abstract][Full Text] [Related]
11. Prediction of relapse in schizophrenia.
Lieberman JA; Kane JM; Sarantakos S; Gadaleta D; Woerner M; Alvir J; Ramos-Lorenzi J
Arch Gen Psychiatry; 1987 Jul; 44(7):597-603. PubMed ID: 2886110
[TBL] [Abstract][Full Text] [Related]
12. The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance.
Kay SR; Singh MM
Arch Gen Psychiatry; 1989 Aug; 46(8):711-8. PubMed ID: 2568824
[TBL] [Abstract][Full Text] [Related]
13. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
Jolley AG; Hirsch SR; McRink A; Manchanda R
BMJ; 1989 Apr; 298(6679):985-90. PubMed ID: 2567190
[TBL] [Abstract][Full Text] [Related]
14. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
15. Carbamazepine as an adjunct of antipsychotic therapy.
Dose M; Apelt S; Emrich HM
Psychiatry Res; 1987 Dec; 22(4):303-10. PubMed ID: 3324137
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
[TBL] [Abstract][Full Text] [Related]
17. Exacerbation of psychosis after discontinuation of carbamazepine treatment.
Heh CW; Sramek J; Herrera J; Costa J
Am J Psychiatry; 1988 Jul; 145(7):878-9. PubMed ID: 2898213
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy and the natural course of schizophrenia.
Davis JM
J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
[TBL] [Abstract][Full Text] [Related]
20. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
Llorca PM; Wolf MA; Lançon C; Bougerol T
Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
